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Abstract
Background: Phosphodiesterases are an important protein family that catalyse the hydrolysis of
cyclic nucleotide monophosphates (cAMP and cGMP), second intracellular messengers responsible
for transducing a variety of extra-cellular signals. A number of different splice variants have been
observed for the human phosphodiesterase 9A gene, a cGMP-specific high-affinity PDE. These
mRNAs differ in the use of specific combinations of exons located at the 5' end of the gene while
the 3' half, that codes for the catalytic domain of the protein, always has the same combination of
exons. It was observed that to deduce the protein sequence with the catalytic domain from all the
variants, at least two ATG start codons have to be used. Alternatively some variants code for
shorter non-functional polypeptides.
Results: In the present study, we expressed different splice variants of PDE9A in HeLa and Cos-
1 cells with EGFP fluorescent protein in phase with the catalytic domain sequence in order to test
the different start codon usage in each splice variant. It was found that at least two ATG start
codons may be used and that the open reading frame that includes the catalytic domain may be
translated. In addition the proteins produced from some of the splice variants are targeted to
membrane ruffles and cellular vesicles while other variants appear to be cytoplasmic. A hypothesis
about the functional meaning of these results is discussed.
Conclusion: Our data suggest the utilization of two different start codons to produce a variety of
different PDE9A proteins, allowing specific subcellular location of PDE9A splice variants.
Background
Cyclic nucleotide monophosphates (cAMP and cGMP)
are ubiquitous second intracellular messengers which
play an essential role in the transduction of a variety of
extracellular signals. The control of intracellular cyclic
nucleotide levels is achieved by different enzymes, includ-
ing cyclases that synthesize the cyclic nucleotides and cat-
abolic enzymes such as cyclic nucleotide
phosphodiesterases (PDEs). At least twenty one genes
coding for cyclic nucleotide PDEs have been identified in
mammals. They have been classified in 11 families and in
humans they code for more than 60 different isoforms
through alternative splicing [1-3].
The PDE9A gene encodes a cGMP-specific high-affinity
PDE with widespread expression in most of the tissues
examined [4-6]. The human PDE9A gene is located on
21q22.3, and has at least 22 exons spanning 122 kb.
Published: 08 November 2006
BMC Molecular Biology 2006, 7:39 doi:10.1186/1471-2199-7-39
Received: 18 July 2006
Accepted: 08 November 2006
This article is available from: http://www.biomedcentral.com/1471-2199/7/39
© 2006 Rentero and Puigdomènech; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.BMC Molecular Biology 2006, 7:39 http://www.biomedcentral.com/1471-2199/7/39
Page 2 of 9
(page number not for citation purposes)
Because of its mapping position PDE9A is a possible can-
didate for genetic diseases mapped on 21q22.3, such as
bipolar affective disorder. Furthermore, its overexpression
might be involved in Down's syndrome [5]. For these rea-
sons the expression in brain tissues of PDE9A, and also
other PDEs, has been studied [7-9]. BAY 73–6691, a
potent and selective PDE9A inhibitor, is currently under
preclinical development for the treatment of Alzheimer's
disease [10].
At least 20 different human PDE9A mRNA transcripts
have been so far identified by EST analysis and sequencing
of PCR amplification of cDNAs from different tissues,
which are produced as a result of alternative splicing of 5'
exons [4,5,11]. However, based on 5'RACE [8] and EST
studies, there is only one alternative splice variant (equiv-
alent to human PDE9A2 variant) that is present in mouse
and rat. This result may indicate an important difference
in the regulation of this gene in human and rodents at the
level of splicing. These 20 different PDE9A splice variants
could present different translation start codons to produce
the functional protein. This mechanism has been
described previously in other PDEs (PDE8A [12],
PDE4D2 [13] and PDE7B [14]) but it has not yet been fur-
ther studied. A complete review has been recently pub-
lished summarizing the current efforts to understand the
specific roles and functions of alternative splicing in meta-
zoan [15].
The cyclic nucleotide-mediated pathways are regulated by
a complex signalling system involving multienzyme fam-
ilies of adenylyl (AC) and guanylyl cyclases (GC), protein
kinase A (PKA) and cGMP-dependent protein kinases
(cGK), and cyclic nucleotide phosphodiesterases. One of
the most important points of this signalling system is the
cyclic nucleotide compartmentalization, which has been
observed for cAMP in a number of cell types [16-18]. This
can arise through the distinct intracellular localization of
separate AC isoforms, the specific intracellular targeting of
PDE isoforms, and the binding of PKA isoforms to specific
anchoring proteins. For example, there are different PDE4
isoforms which have specific intracellular targeting
[19,20], and interact with scaffolding proteins [21,22],
due to the modification of specific N-terminal regions via
alternatively spliced mRNAs in their 5' regions.
In this study we report the differential usage of PDE9A
translation start sites depending on the splice variant,
allowing the synthesis of a variety of PDE9A polypeptides
that differ in their N-terminal regions. We also show the
differential subcellular localization of certain PDE9A
splice variants with different start codons that may have
consequences for compartmentalization of cGMP signal-
ling.
Results and Discussion
Different start codon usage of PDE9A splice variants
PDE9A has a large number of alternative splice variants
that produce a number of mRNAs differing in their 5'
region while the 3' domain that contains the region cod-
ing for the catalytic site of the enzyme is present in all
cases. During this work, a new PDE9A splice variant called
PDE9A21 (GenBank Accession Number AY701187) has
been found by RT-PCR from human colon mRNA, which
adds to the 20 splice variants previously described [4,5].
The sequence analysis of the predicted proteins indicated
that if the open reading frame has to include, in phase, the
PDE9A catalytic domain sequence in all the variants, a
number of the different possible start codons (ATGs)
could be used, depending on the splice variant [4].
According to the predicted sequence on the PDE9A1 and
PDE9A2 splice variants (see Figure 1A), the first start
codon in exon 1 is in phase with the complete ORF which
has the catalytic domain. Using this ATG, other splice var-
iants like PDE9A3 and PDE9A17 give two short proteins
(61 and 78 amino acids respectively) due to early stop
codons found in their ORF (in exons 6 and 5, respec-
tively). However, there is a second ATG 52 bases down-
stream from the first one, also located on exon 1, in a
shifted reading frame, which could be the start codon in
PDE9A3 and PDE9A17, resulting in slightly shorter
PDE9A proteins but having a complete catalytic domain.
Figure 1B shows the schematic amino terminal represen-
tation of these splice variants. Therefore, this situation
might lead either to the use of the first ATG, giving rise to
a truncated protein, or to the use of a different down-
stream ATG that would produce a protein with a different
N-terminus but that would include the catalytic domain.
These four splice variants represent most of the PDE9A
splice variants and would help us to clarify the usage of
the different start codon in those transcripts.
In order to test these possibilities, cDNAs corresponding
to the PDE9A1, PDE9A2, PDE9A3, and PDE9A17 splice
variants were cloned in the pEGFP-N1 expression vector
to create fusion proteins between the predicted ORF of the
specific PDE9A isoform and that of EGFP fluorescent pro-
tein, and then they were transiently expressed in both
Cos-1 and HeLa cells. The cDNAs were cloned with 53
nucleotides of the 5'-untranslated region (5'UTR) of
PDE9A1 (from the theoretical ATG start codon of
PDE9A1) and 105 nucleotides of the 5'UTR of PDE9A3
and PDE9A17 (from the theoretical ATG start codon of
PDE9A3) (see Figure 1A). This region was obtained by 5'
RACE on the longest cDNAs cloned [4]. These clones
express the PDE9A splice variant followed by a GFP fluo-
rescent protein in the C-terminal of the chimeric protein.
All constructs were sequenced and the GFP sequence was,
in all cases, in phase with the PDE9A catalytic domain. NoBMC Molecular Biology 2006, 7:39 http://www.biomedcentral.com/1471-2199/7/39
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changes in the sequence of the predicted PDE9A or GFP
protein were observed.
The expression of the four PDE9A splice variants (PDEs
9A1, 9A2, 9A3 and 9A17) fused to GFP were tested in tran-
siently transfected Cos-1 cells by immunoblotting analy-
sis using both anti-GFP (see Figure 2A) and anti-PDE9A
sera (data not shown). All splice variants (plus GFP) were
detected with both antibodies and they show their pre-
dicted molecular mass (96.1, 88.6, 81.4, and 91 kDa
respectively), revealing that both start codons were used
by the cell to produce the chimeric PDE9A-GFP protein.
The same results were obtained expressing these con-
structs in HeLa cells (data not shown). It may then be con-
cluded that in the different splice variants of PDE9A, a
variety of polypeptides with different N-terminal
sequences but containing the catalytic domain are pro-
duced by the use of two different start codons present in
exon 1.
Observing the mRNA initial sequence of PDE9A, a previ-
ously described hairpin structure [6] could be seen (Figure
2C), which could be the responsible element of a post-
transcriptional regulation of PDE9A splice variants. There
are some examples of proteins whose translation is
affected by 5'UTR hairpin, such as ornithine decarboxy-
lase translation inhibition, which is regulated together by
its 5'UTR and enzymatic products [23]. Having a close
look around exon 1 start codons sequence context and
comparing them with Kozak consensus sequence (Figure
2B, and reviewed in [24]) we could see that the first start
codon presents an optimal context for initiation of trans-
Sequence and structure of the N-terminus region of human PDE9A splice variants Figure 1
Sequence and structure of the N-terminus region of human PDE9A splice variants. (A) Sequences of the initial sec-
tion of the PDE9A gene. The different ATGs are indicated by boxes and the predicted start codons for the different splice var-
iants by wide arrows. (B) Structure of the 5' region of the human PDE9A splice variants. The exons are schematically illustrated 
by boxes, the 5'UTR by black lines, and the spliced exons by dotted lines. The amino acid sequence deduced from a shifted 
frame start codon is illustrated by hatched boxes, black triangles indicate the myristoylation motif location, white triangles indi-
cate the pat7 motif location, and asterisks indicated other ATGs present in this sequence.BMC Molecular Biology 2006, 7:39 http://www.biomedcentral.com/1471-2199/7/39
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lation in mammals at sequence level, which could be
affected by the secondary structure of the mRNA. On the
other hand, the second start codon presents a weak or sub-
optimal context due to the pyrimidine on -3 position, but
it might probably not be influenced by the inhibitory
effect of the hairpin located upstream.
The different start codon usage in exon 1 reported here
allows the differential translation of protein domains like
the N-myristoylation motif present in the protein
sequence region. A similar situation may be supposed to
occur with the expression of splice variants of other PDEs
such as PDE8A3, 4 and 5 splice variants [12], human
PDE4D splice variants [13], and rat PDE7B2 splice variant
[14] therefore producing a variety of proteins that differ in
their N-terminus. Recent findings also show an increasing
number of genes (like FGF2 [25]) with IRES elements
(internal ribosome entry site elements) that regulate their
translation by a balance between the cap-dependent and
IRES-mediated expression to produce several proteins
(reviewed in [26]).
Intracellular location of PDE9A splice variants in 
transfected HeLa and Cos-1 cells
In a number of other PDE proteins it was found that the
protein structure contains a phosphodiesterase catalytic
Differential start codon usage in PDE9A splice variants Figure 2
Differential start codon usage in PDE9A splice variants. (A) Western blot analysis of the expression of the chimeric 
PDE9A splice variants fused to GFP. GFP-fused proteins of PDE9A1 (lane 1, 96 kDa), the N-terminal region of PDE9A1 (lane 2, 
62 kDa), PDE9A2 (lane 3, 89 kDa), PDE9A3 (lane 4, 81 kDa), and PDE9A17 (lane 5, 91 kDa) were produced in transfected 
Cos-1 cells, and were immunoblotted using a rabbit anti-GFP serum (1:1000). (B) Sequence comparison between Kozak con-
sensus motif and PDE9A start codons, where the critical -3 and +4 positions are marked. (C) Schematic secondary structure 
representation of PDE9A exon 1 sequence. Start codons are emphasized by grey boxes.BMC Molecular Biology 2006, 7:39 http://www.biomedcentral.com/1471-2199/7/39
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domain in the C-terminus of the protein, and several dif-
ferent regions in the N-terminus produced by differential
splicing of the exons. This situation provided a large
number of different proteins which properties differ in the
regulation of catalytic activity. They may include a cleav-
age site for caspase activities (rnPDE4A5) [27], a site for
protein-protein interactions (SH3 domains in rnPDE4A5)
[27], or consensus sequences for subcellular targeting
(PDE3, rnPDE4A1A) [28,29].
Laser scanning confocal microscopy has been employed
to define the intracellular localization of the proteins pro-
duced by the PDE9A1, PDE9A2, PDE9A3 and PDE9A17
splice variants. For this analysis, cDNAs corresponding to
the different splice variants were transiently transfected in
HeLa and Cos-1 cells with the GFP protein fused in the
carboxy terminal region, and with the CFP protein fused
in both the carboxy and amino terminal region of the pre-
dicted proteins, obtaining very similar results. The strategy
chosen for the study has been to express the different
PDE9A polypeptides in cultured cells. Expressing tagged-
proteins in cases where no useful antibodies are available
may be the only way to detect the location of the proteins
within the cell, and fusing the tag in both the carboxy and
amino terminal region maximize the reliability of this
approximation.
This study revealed that PDE9A1 is predominantly local-
ized in the membrane ruffles at the cell margin, but it is
also directed to a discrete perinuclear location (Figure 3a
and 3b), Golgi apparatus (Figure 4B), intracellular vesi-
cles, and weakly to endoplasmic reticulum (Figure 4A). In
the detailed image (Figure 3b) the membrane and mem-
brane ruffle association of PDE9A1 is visible as well as the
location in vesicles. However, the amino terminal
PDE9A1 construction (residues 1–304), lacking the C-ter-
minal region that contains the catalytic domain, was not
clearly expressed in the cell margin, but was distributed
throughout the cell cytosol (Figure 3c). The carboxy termi-
nal PDE9A construction, spanning the catalytic domain
and the extreme carboxy terminal region of PDE9A (resi-
dues 271–593 of PDE9A1), was also distributed all
around the cytosol (Figure 3d). A weak nuclear expression
was detected in this construction, while PDE9A1 expres-
sion was excluded from the nucleus in all cases (Figure 3a
and 3c). There was a high level of PDE9A2 in membrane
ruffles and in the perinuclear region (Figure 3e). However,
it was also present in other cell membrane regions. In vivo
fluorescence microscopy of HeLa cells transiently trans-
fected with PDE9A1-GFP and PDE9A2-GFP constructs
and stained with FM4-64 has revealed the co-localization
of PDE9A-GFP chimeric proteins and the fluorescent
membrane tracer (Figure 4C). The reticular location of
PDE9A2-GFP chimeric protein could also be observed in
these images. The PDE9A3 and PDE9A17 splice variants,
on the other hand, seem to have lost the targeting towards
a cortical region having, instead, a cytosolic location (Fig-
ure 3f and 3g) and a weak colocalization with the endo-
plasmic reticulum (Figure 4A). In these cases there was a
clear definition of the cell outline, which was missing
from the control GFP expression (Figure 3h).
Different cellular location of the PDE9A splice variants
may be regulated by the N-terminus region, which is the
main change in the different splice variants. The analysis
of this region shows that two putative domains (the pat7
and the bipartite motif) for nuclear localization in PDE9A
are found in this region. The pat7 signal is present in
splice variants 1 and 17 (exon 5, sequence PLRDRRV),
and the bipartite signal is present in all splice variants
studied (exon 19, sequence KKTDSLTSGATEKSRER). In
contrast to our data, Wang and colleagues [30] found a
pat7-dependent nuclear location or PDE9A1, whereas our
chimeric constructions with the pat7 signal have never
given a nuclear location. There is an N-myristoylation pat-
tern (MGSGSSS) in the first amino acids of PDE9A1 and
PDE9A2 (only in splice variants which utilize the first start
codon in exon 1), which is often related to modifications
leading to a membrane attachment. The presence of
PDE9A1 in the Golgi apparatus is consistent with post-
translational myristoylation, which is done in this cellular
compartment.
The results obtained above indicate that both the amino
and carboxy terminal regions take part in the regulation of
the cellular localization of PDE9A, because only the com-
plete sequence is found in the vicinity of the membrane
region while a cytoplasmic location is observed for both
N-terminal and C-terminal isolated regions. However, a
recent structural study suggests that the N-terminal region
of PDE9A does not significantly participate in the regula-
tion of PDE activity [31]. Nevertheless only the longer
splice variants show the specific pattern observed. It could
then be possible that the cellular localization of PDE9A is
regulated by differential splicing, which provides a spe-
cific combination of sequences, and post-translational
modifications allowing a membrane targeting. These dif-
ferent types of modifications may explain the differences
observed in studies that have used different cell types [30].
In this situation, the interaction with another protein or
proteins may be important for the observed localization
of the protein.
The presence of PDE9A splice variants in the vicinity of
the membrane and in other subcellular locations may
allow the regulation of cGMP degradation in cellular
microdomains, which may be in accordance with cyclic
nucleotide regulation due to multiple PDE proteins pres-
ence in each cell. These cellular microdomain locations,
together with co-localization with other pathway signal-BMC Molecular Biology 2006, 7:39 http://www.biomedcentral.com/1471-2199/7/39
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ling molecules probably contribute to both spatial and
temporal regulation of specific cellular signal transduc-
tion.
Conclusion
This study shows that the two start codons of PDE9A
located on exon 1 could produce a variety of polypeptides
with different N-terminal sequences but containing the
catalytic domain. Moreover, these alternative splice vari-
ants present a different subcellular distribution, allowing
the regulation of cGMP degradation in cellular microdo-




The GFP- and CFP-fusion constructs were prepared using
pEGFP-N1, pECFP-N1 and pECFP-C1 (Clontech). Full-
length PDE9A1, PDE9A2, PDE9A3 and PDE9A17
obtained by 5'RACE were PCR cloned into SacI/SmaI sites
of pEGFP-N1 and HindIII/SalI sites of pECFP, resulting in
PDE9A1 and PDE9A2 constructs with 53 nucleotides
before their ATG start codon, and in PDE9A3 and
PDE9A17 constructs with 105 nucleotides before their
hypothetical ATG start codon. Amino terminal sequence
of PDE9A1 (amino acid 1 to 304) and carboxy terminal
sequence of PDE9A (amino acid 271–593 of PDE9A1)
were PCR cloned into SacI/SmaI sites of pEGFP1-N1,
pECFP-N1 and pECFP-C1.
Cell culture and transfection
Cos-1 (African green monkey kidney cell line) and HeLa
cells (human cervix carcinoma cell line) were grown at
37°C under 5% CO2  in Dulbecco's Modified Eagle's
Medium supplemented with 10% foetal bovine serum
and 2 mM L-glutamine.
Cos-1 cells were seeded at about 33% of confluence in
100-mm diameter plates, and were transfected at approx-
imately 50% confluence using the LipofectAMINE PLUS
Intracellular localization of GFP-chimeric PDE9A splice variants in transiently transfected HeLa cells Figure 3
Intracellular localization of GFP-chimeric PDE9A splice variants in transiently transfected HeLa cells. All splice 
variant constructions were cloned with their 5'UTR region as described in Methods. Confocal analysis of: a and b, GFP-carboxy 
terminal-fused proteins of PDE9A1; c, N-terminal region of PDE9A1; d, C-terminal region of PDE9A; e, PDE9A2; f, PDE9A3; g, 
PDE9A17; and h, GFP control. Panel b is a detailed image of GFP-PDE9A1. White arrows indicate the membrane location of 
chimeric proteins.BMC Molecular Biology 2006, 7:39 http://www.biomedcentral.com/1471-2199/7/39
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Intracellular co-location of PDE9A1, PDE9A2 and PDE9A3 Figure 4
Intracellular co-location of PDE9A1, PDE9A2 and PDE9A3. Intracellular co-location of PDE9A1-, PDE9A2- and 
PDE9A3-GFP chimeric proteins with endoplasmic reticulum, Golgi apparatus and membrane markers in transiently transfected 
Cos-1 and HeLa cells. Confocal analysis of PDE9A1-GFP and PDE9A3-GFP with (A) calnexin (endoplasmic reticulum marker) 
and (B) giantin (Golgi apparatus marker). (C) Membrane location of PDE9A1- and PDE9A2-GFP chimeric proteins in tran-
siently transfected HeLa cells by in vivo fluorescence microscopy. Black and white panels show the expression of GFP-carboxy 
terminal-fused proteins and the marker (calnexin, giantin and FM4-64) location, and the coloured image show the merged com-
position of both images. White arrows indicate the co-location of the chimeric proteins with the subcellular markers.BMC Molecular Biology 2006, 7:39 http://www.biomedcentral.com/1471-2199/7/39
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kit (Invitrogen) and 2 µg of each chimeric-DNA construct
per plate. After 24 hours, cells were lysed with lysis buffer
(50 mM HCl-Tris pH 8.0, 150 mM NaCl, 5 mM EDTA,
0.5% Nonidet P-40 and protease inhibitors).
For confocal analyses, HeLa and Cos-1 cells were plated
out onto coverslips (12-mm diameter) at about 33% of
confluence in 35-mm diameter plates, and were trans-
fected at approximately 50% confluence using the Lipo-
fectAMINE PLUS kit and 1.5 µg of each chimeric-DNA
construct per plate. After 24 hours, cells were fixed to the
coverslips using paraformaldehyde 4%. The coverslips
were mounted on glass slides with Mowiol (Calbiochem-
Novabiochem). Calnexin and giantin were visualized
using anti-calnexin [32] and anti-giantin [33] as first anti-
bodies and goat anti-mouse (Alexa594) as secondary anti-
body (Molecular Probes). Samples were washed
extensively and coverslips were mounted with Mowiol.
For fluorescence microscopy, HeLa and Cos-1 cells were
plated out onto 22-mm diameter coverslips and trans-
fected as described above. 24 hours after transfection, cell
membranes were stained with the fluorescent lipophilic
tracer FM4-64 (Molecular Probes) during 2 minutes in FM
buffer (130 mM NaCl, 5 mM KCl, 2 mM CaCl2, 1 mM
MgSO4, 0.8 mM Na2H(PO4), 0.2 mM NaH2(PO4), 25 mM
glucose, and 20 mM HEPES). In vivo fluorescence micros-
copy was then performed.
SDS-PAGE and western blotting
Rabbit polyclonal anti-PDE9A antibody was generated
from the carboxy terminal fragment of PDE9A (amino
acids 127 to 534). Briefly, this PDE9A C-terminal frag-
ment was cloned in pET14b, expressed in E. coli BL21, and
the His-tagged protein was purified by immobilised metal
ion chromatography on Ni2+-nitriloacetic acid agarose
(Ni-NTA). One microgram of purified recombinant pro-
tein was subcutaneously injected in presence of complete
adjuvant (complete Freunds adjuvant) into New Zealand
White rabbit, followed by two booster immunizations
with incomplete adjuvant (incomplete Freunds adjuvant)
3 and 6 weeks after the priming immunization. After week
8 the animal was bled and serum prepared from whole
blood.
For detection of chimeric PDE9A proteins by western blot,
10 µg of each lysate were boiled in Laemmly buffer [34],
were separated by SDS/PAGE and transfered to nitrocellu-
lose, followed by incubation with primary antibodies
(anti-PDE9A and anti-GFP (Roche Applied Science)), the
appropriated peroxidise-conjugated secondary antibodies
(Jackson Immunoresearch) and ECL detection (Amer-
sham Pharmacia).
Confocal microscopy
Confocal microscopy was performed using a Leica TCS SP
confocal laser scanning microscope fitted with spectro-
photometers for emission band wavelength selection. An
argon ion laser emitting at 488 and 458 nm was used to
excite EGFP and ECFP respectively. During EGFP scan-
ning, we used a triple-dichroic beam splitter (TD 488/
543/633), the emission window set at 495–540 nm and a
63 × oil immersion objective. For ECFP scanning, a dou-
ble-dichroic beam splitter (DD 458/514) was used, the
emission window was set at 469–503 nm and a 63 × oil
immersion objective was used. Serial optical slices of 0.5
µm were taken. Confocal image stacks were combined as
x-y projection images.
List of abbreviations
PDE, cyclic nucleotide phosphodiesterase; cAMP and
cGMP, cyclic adenosine and guanosine monophosphate;
EGFP and ECFP, enhanced green and cyan fluorescent
proteins; 5'UTR, 5'-untranslated region; IRES, internal
ribosome entry sites.
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